Negative NICE Recommendation for Abraxane in Pancreatic Cancer
NICE (the National Institute for Health and Care Excellence) has issued its Final Appraisal Determination (FAD) on Abraxane (paclitaxel formulated as albumin bound nanoparticles; nab-paclitaxel) in combination with gemcitabine, and has not recommended it for use by NHS England for the treatment of metastatic adenocarcinoma of the pancreas.
In addition, an NHS England review of 42 cancer treatments currently available through the Cancer Drugs Fund (CDF) could result in Abraxane being ‘de-listed’, despite being added to the list earlier this year and the All Wales Medicines Strategy Group (AWMSG) recommending it for use. Abraxane in combination with gemcitabine was added to the CDF in March 2014, following support from 70 leading pancreatic cancer specialists to include it on the list. So far over 260 metastatic pancreatic cancer patients have been able to access Abraxane through the CDF.
Professor Will Steward, Professor of Medical Oncology in Leicester, said: “This is very depressing news for patients with metastatic pancreatic cancer who already have very limited treatment options. This negative NICE decision means that hundreds of patients with metastatic pancreatic cancer, who could potentially benefit from Abraxane, will not have access to it. For a cancer which has such poor survival rates, this is a very sad decision by NICE and now leaves clinicians with limited treatment options.”
Ms Alex Ford, Chief Executive of Pancreatic Cancer UK, said: “This is an extremely worrying time for pancreatic cancer patients and their families. The NICE decision and the review by the CDF which could lead to Abraxane being removed from the CDF, is devastating news for patients with metastatic pancreatic cancer who currently have very few treatment options. Pancreatic Cancer UK calls for NICE to reconsider so that metastatic pancreatic cancer patients in England and Wales are able to benefit from this treatment.”
Ali Stunt, Founder and CEO of Pancreatic Cancer Action, said: “We are outraged that the first licensed and clinically effective treatment for pancreatic cancer in over 7 years has not been approved by NICE. Patients with pancreatic cancer already have a very poor prognosis and limited treatment options. Today’s decision is a backward step by NICE and with the ambiguity surrounding the funding of Abraxane on the CDF, this is an extremely anxious time for future patients with metastatic pancreatic cancer.”
Dr Adrian Kilcoyne, Medical Director, Celgene UK & Ireland, said: “It is very disappointing that NICE did not recommend Abraxane despite the fact they recognised that grounds for end of life could be considered. This decision is a serious setback for both clinicians and patients with metastatic pancreatic cancer.”
“In addition, the potential de-listing of Abraxane from the CDF could mean that patients will not be able to access Abraxane on the NHS in England despite the product in combination with gemcitabine being shown to be clinically effective for previously untreated metastatic pancreatic cancer. We urge NHS England to carefully consider this when decisions are finalised in early January as patients have extremely limited treatment options and the prognosis for pancreatic cancer is so poor, a point which NICE themselves acknowledged in the final appraisal determination.”
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance